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Microbiome as the next frontier for gut-targeted drugs
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Using in vitro models for assessing drug-bug crosstalk
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Interactions between microbial- and host-derived metabolism
• CX impacted butyrate
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• Bacterially-exposed CX decreased inflammation
Long term
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• Butyrate follows same trend 
observed in the batch
• CX impacts bacterial protein 
synthesis activity in mucus
• CX triggers translocation of Megamonas from 
mucus to lumen compartment
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• Microbiome functionality (GC)
• Community composition (NGS)
• Host interactions (cell models)
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